Acute Respiratory Distress Syndrome (ARDS) Market Report 2026

Acute Respiratory Distress Syndrome (ARDS) Market Overview

• Acute Respiratory Distress Syndrome (ARDS) market size has reached to $1.41 billion in 2025 • Expected to grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 11.7% • Growth Driver: Increasing Number Of Respiratory Illness Are Anticipated To Positively Impact The Acute Respiratory Distress Syndrome (ARDS) Market • Market Trend: Innovations In Immune Modulators Offer New Therapeutic Options In Acute Respiratory Distress Syndrome (ARDS) • North America was the largest region in 2025.

What Is Covered Under Acute Respiratory Distress Syndrome (ARDS) Market?

Acute respiratory distress syndrome (ARDS) is a potentially fatal illness characterized by non-compliant, or stiff lungs and low oxygenation. It is an acute, diffuse and inflammatory form of lung injury that can occur in seriously ill patients. Acute respiratory distress syndrome (ARDS) treatment involves mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygenation and prevent lung injury. The main types of services involved in acute respiratory distress syndrome (ARDS) are diagnosis and treatment. Diagnosis is the process of separating a disease or disorder from other potential disorders and defining its nature. The diagnosis of acute respiratory distress syndrome (ARDS) is based on the physical exam, chest X-ray and oxygen levels. It can be caused by COVID-19 disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia and others with severity ranging from mild, moderate and severe. The major end users are hospitals, clinics, ambulatory service centers and others.

What Is The Acute Respiratory Distress Syndrome (ARDS) Market Growth Forecast?

The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to technological advancements in mechanical ventilation and ecmo systems, increasing r&d in ards therapeutics, expansion of critical care units globally, rising investment in personalized patient management solutions, growing prevalence of severe pneumonia and sepsis. Major trends in the forecast period include rising adoption of mechanical ventilation and ecmo devices, increasing prevalence of ards due to covid-19 and other respiratory diseases, growing use of advanced diagnostic tests for early detection, expansion of critical care and icu facilities, focus on personalized and supportive care management.

Global Acute Respiratory Distress Syndrome (ARDS) Market Segmentation

1) By Type: Diagnosis, Treatment 2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes 3) By Severity: Mild, Moderate, Severe 4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users Subsegments: 1) By Diagnosis: Imaging Tests, Blood Tests 2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care

What Is The Driver Of The Acute Respiratory Distress Syndrome (ARDS) Market?

The increasing number of respiratory illnesses is expected to propel the growth of the acute respiratory distress syndrome (ARDS) market going forward. Respiratory illness refers to a group of medical conditions that affect the respiratory system, including the airways and lungs, and can cause difficulty breathing. The increasing number of respiratory illnesses, like COVID-19, is one of the major factors driving the growth of the acute respiratory distress syndrome (ARDS) market. As more people develop respiratory illnesses, the demand for ARDS treatments and therapies is likely to increase, leading to market growth. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, in 2023, Australia recorded a total of 474 asthma-related deaths, comprising 325 females and 149 males. This figure is almost identical to the 473 asthma-related deaths reported in 2022, highlighting a consistent trend in asthma mortality over the two years. Therefore, the increasing number of respiratory illnesses is driving the growth of the acute respiratory distress syndrome (ARDS) industry.

Key Players In The Global Acute Respiratory Distress Syndrome (ARDS) Market

Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy

Global Acute Respiratory Distress Syndrome (ARDS) Market Trends and Insights

Major companies operating in the acute respiratory distress syndrome market are focusing on developing advanced immune modulators to enhance patient survival and reduce inflammation. Immune modulators are therapies that restore immune balance by targeting dysfunctional inflammatory pathways without suppressing overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage company, received FDA Fast Track designation for its lead product, recombinant human plasma gelsolin (rhu-pGSN), for the treatment of ARDS. The therapy works by replenishing gelsolin, a critical immune regulatory protein, to modulate NLRP3 inflammasome activation, enhance microbial clearance, remove toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is being evaluated in a 600-patient global Phase 2b trial for moderate to severe ARDS and may also be made available through the FDA Expanded Access or Compassionate Use program. The Fast Track designation allows for expedited regulatory interactions, rolling review of marketing applications, and eligibility for priority review, potentially accelerating its time to market and offering a novel therapeutic option for patients with limited alternatives.

What Are Latest Mergers And Acquisitions In The Acute Respiratory Distress Syndrome (ARDS) Market?

In April 2024, Healios K.K., a Japan-based regenerative medicine-focused biotech company, acquired all of the assets of Athersys, Inc., including its off-the-shelf stem cell therapy MultiStem (invimestrocel), via a credit bid of approximately $2.25 million. Through this acquisition, Healios gains full control of the MultiStem intellectual property and R&D capabilities, enabling it to further develop the therapy globally, especially for acute respiratory distress syndrome (ARDS). Athersys, Inc. is a US-based provider of acute respiratory distress syndrome.

Regional Outlook

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Respiratory Distress Syndrome (ARDS) Market?

The acute respiratory distress syndrome (ARDS) market includes revenues earned by entities by providing resolution and recovery services, medication, supplemental oxygen and mechanical ventilation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute respiratory distress syndrome (ARDS) market consists of sales of neuromuscular blockers, corticosteroids, monitoring devices, diagnostic devices and therapeutic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Respiratory Distress Syndrome (ARDS) Market Report 2026?

The acute respiratory distress syndrome (ards) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute respiratory distress syndrome (ards) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.